The Science (and Myths) of GLP-1 Weight Loss Drugs

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.com


This week on the podcast, Mikki speaks to Dr Spencer Nadolsky — a board-certified obesity and lipid specialist known for his evidence-based, compassionate approach to helping people lose weight and improve metabolic health. Spencer has dedicated his career to bridging the gap between clinical medicine and the lived realities of people struggling with obesity, cutting through misinformation to focus on what actually works.
With the arrival of Wegovy in New Zealand — and the explosion of interest in GLP-1 medications worldwide — their conversation couldn’t be more timely. They discuss how these drugs work, how they compare to diet, lifestyle, and older weight loss medications, and why the price tag varies so widely between countries. They also explore the controversies — from “microdosing” to long-term safety, tolerance, and muscle loss — and whether these drugs can genuinely shift someone’s metabolic set point or are simply managing symptoms.
 
If you’ve been wondering whether GLP-1s are game-changing tools or just the latest fad, this episode will help separate the hype from the evidence.
 
Dr. Spencer Nadolsky is an obesity and lipid specialist (DO, ABOM, ABCL) with over a decade of experience. Through practice innovation, digital education, and previous ventures like Sequence and the Docs Who Lift podcast, he’s become a trusted, engaging voice in metabolic health.
His company, Vineyard, is a virtual obesity medicine clinic delivering personalized, science-backed, and compassionate care. Patients benefit from direct physician access, fast support, individualized plans, and ongoing research—all focused on long-term health, not quick solutions.
 

Creators and Guests

Mikki Williden
Host
Mikki Williden
X Instagram Website Link